Bio-Techne at Morgan Stanley Conference: Strategic Insights on Growth and Challenges

Bio-Techne Corp. (NASDAQ:TECH) reported 3% revenue growth in its latest quarter, with 90% recurring revenue, during its presentation at the Morgan Stanley Global Healthcare Conference. CFO Jim Hippel highlighted strong double-digit growth in large pharma and 10% growth in China (though influenced by tariff pull-ins), while spatial biology underperformed due to shipment delays and biotech faced funding challenges resulting in low single-digit growth. The company, which sees 45% of revenue from new growth areas like automation and cell therapy, anticipates continued low single-digit growth amidst political and funding uncertainties, but remains optimistic about long-term prospects driven by megatrends and its strong positioning in cell and gene therapy, particularly its $60M run-rate GMP protein business, and ProteinSimple platforms. The strategic divestiture of Exosome Diagnostics was noted as a move to reallocate resources to core capabilities.

Analysis

Bio-Techne Corp. (TECH) is navigating a mixed operating environment, characterized by pockets of strength offset by specific end-market headwinds. The company delivered 3% revenue growth in its latest quarter, underpinned by a highly resilient model with 90% recurring revenue. Key growth drivers included the large pharma segment, which posted double-digit growth for the second consecutive quarter, and a notable 10% growth in China, although this figure was inflated by instrument tariff pull-ins. The underlying flattish performance in China is still a significant improvement from prior years. However, these gains were tempered by challenges, including underperformance in spatial biology due to shipment delays of its high-value COMET instruments and pronounced uncertainty in the biotech sector, which is experiencing low single-digit growth amid a 35% year-to-date drop in funding. The academic market, representing over 20% of revenue, also faces pressure from U.S. funding constraints. Strategically, the divestiture of the non-core Exosome Diagnostics business sharpens the company's focus and reallocates resources toward high-potential areas like its rapidly expanding GMP protein business ($60 million run rate) and its resilient ProteinSimple automation platforms. The company's cautious low single-digit growth outlook reflects these near-term political and funding uncertainties, which management views as temporary noise rather than a structural shift, expressing long-term optimism based on megatrends and its strong positioning in cell therapy and lab automation.

Key Decisions for Investors

• Investors should closely monitor the biotech funding environment and U.S. academic budget resolutions, as these are the primary headwinds tempering the company's near-term, low single-digit growth guidance.
• For long-term investors, the current caution may present an opportunity, as the company's strategic positioning in high-growth markets like cell and gene therapy and lab automation remains robust and is now sharpened by the divestiture of the non-core Exosome unit.
• It is crucial to track the performance of the biopharma segment, which constitutes 50% of revenue, for any signs of a slowdown in the resilient large pharma space or further weakness in the funding-sensitive biotech segment, which management identified as the biggest wild card.
• The sustainability of China's recovery, beyond the one-off tariff pull-ins, represents a key potential upside catalyst, and its return to consistent growth would be a significant positive signal for the outlook.